IL-18 and Subcapsular Lymph Node Macrophages are Essential for Enhanced B Cell Responses with TLR4 Agonist Adjuvants
Open Access
- 1 December 2016
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 197 (11) , 4351-4359
Abstract
Designing modern vaccine adjuvants depends on understanding the cellular and molecular events that connect innate and adaptive immune responses. The synthetic TLR4 agonist glycopyranosyl lipid adjuvant (GLA) formulated in a squalene-in-water emulsion (GLA-SE) augments both cellular and humoral immune responses to vaccine Ags. This adjuvant is currently included in several vaccines undergoing clinical evaluation including those for tuberculosis, leishmaniasis, and influenza. Delineation of the mechanisms of adjuvant activity will enable more informative evaluation of clinical trials. Early after injection, GLA-SE induces substantially more Ag-specific B cells, higher serum Ab titers, and greater numbers of T follicular helper (TFH) and Th1 cells than alum, the SE alone, or GLA without SE. GLA-SE augments Ag-specific B cell differentiation into germinal center and memory precursor B cells as well as preplasmablasts that rapidly secrete Abs. CD169+ SIGNR1+ subcapsular medullary macrophages are the primary cells to take up GLA-SE after immunization and are critical for the innate immune responses, including rapid IL-18 production, induced by GLA-SE. Depletion of subcapsular macrophages (SCMф) or abrogation of IL-18 signaling dramatically impairs the Ag-specific B cell and Ab responses augmented by GLA-SE. Depletion of SCMф also drastically reduces the Th1 but not the TFH response. Thus the GLA-SE adjuvant operates through interaction with IL-18–producing SCMф for the rapid induction of B cell expansion and differentiation, Ab secretion, and Th1 responses, whereas augmentation of TFH numbers by GLA-SE is independent of SCMф.This publication has 49 references indexed in Scilit:
- Cross-species protection: Schistosoma mansoni Sm-p80 vaccine confers protection against Schistosoma haematobium in hamsters and baboonsVaccine, 2014
- Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosisJournal of Controlled Release, 2013
- Cytoplasmic LPS Activates Caspase-11: Implications in TLR4-Independent Endotoxic ShockScience, 2013
- Adjuvant solution for pandemic influenza vaccine productionProceedings of the National Academy of Sciences, 2012
- The mechanism of action of MF59 – An innately attractive adjuvant formulationVaccine, 2012
- Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88Proceedings of the National Academy of Sciences, 2011
- Development and Characterization of Synthetic Glucopyranosyl Lipid Adjuvant System as a Vaccine AdjuvantPLOS ONE, 2011
- Physicochemical characterization and biological activity of synthetic TLR4 agonist formulationsColloids and Surfaces B: Biointerfaces, 2010
- Diphtheria toxin receptor–mediated conditional and targeted cell ablation in transgenic miceNature Biotechnology, 2001
- Th1 and Th2 CD4+ T Cells Provide Help for B Cell Clonal Expansion and Antibody Synthesis in a Similar Manner In VivoThe Journal of Immunology, 2000